A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE compares different available treatments for stroke prevention in patients with non-valvular atrial...
Left Atrial Appendage (LAA) Occluders
-
-
St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the company’s Amplatzer Amulet Left Atrial Appendage (LAA) Occluder. The trial will evaluate the...
-
-
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA).
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.
Feature | Left Atrial Appendage (LAA) Occluders | September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to...
News | Left Atrial Appendage (LAA) Occluders | April 25, 2017
April 25, 2017 — AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion...
The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.
Feature | Left Atrial Appendage (LAA) Occluders | March 29, 2017
March 29, 2017 — For patients with...
Technology | Left Atrial Appendage (LAA) Occluders | March 22, 2017
March 22, 2017 — Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption...
Dr. Dee Dee Wang with part of Henry Ford Hospital's collection of 3-D printed hearts used for education and to preplan structural heart procedures.
Feature | 3-D Printing | March 03, 2017
March 3, 2017 — A Henry Ford Hospital study found a 100 percent success rate in left atrial appendage (LAA)...
News | Left Atrial Appendage (LAA) Occluders | January 06, 2017
January 6, 2017 — SentreHeart Inc. announced that it has completed the Stage I enrollment milestone in the aMAZE...
Feature | Left Atrial Appendage (LAA) Occluders | November 07, 2016
November 7, 2016 – Results from the U.S. real-world, post-FDA approval experience of the Watchman device found high...
News | Atrial Fibrillation | October 25, 2016
October 25, 2016 — A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE ...
News | Left Atrial Appendage (LAA) Occluders | October 20, 2016
October 20, 2016 — SentreHeart Inc. announced in late September the closing of a $35 million Series D round of...
News | Left Atrial Appendage (LAA) Occluders | October 13, 2016
October 13, 2016 — SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical...
The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently.
Feature | Heart Failure | September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with...
News | Left Atrial Appendage (LAA) Occluders | September 02, 2016
September 2, 2016 — St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of...
The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves.
Feature | August 05, 2016 | Dave Fornell
August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional...
An illustration of a Watchman transcatheter LAA occluder being implanted.
Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in...
News | Left Atrial Appendage (LAA) Occluders | July 07, 2016
July 7, 2016 — AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont...
